

Supplement 1: Demographics of patient cohort

Sex	Age (y)	Inflammatory disease	biological DMARD	conventional DMARD	Steroids
f	43	Psoriatic Arthritis	Golimumab	Leflunomide	5 mg Prednisolone
f	35	Psoriatic Arthritis	Certolizumab pegol	-	-
f	43	Rheumatoid Arthritis	Certolizumab pegol	-	5 mg Prednisolone
m	46	MCTD	-	Hydroxychloroquine	-
f	39	Rheumatoid Arthritis	Etanercept	Leflunomide	-
f	51	Rheumatoid Arthritis	-	Sulfasalazine	-
f	65	Spondyloarthropathy	Infliximab	-	-
m	38	Spondyloarthropathy	Etanercept	-	-
f	45	Sarcoidosis	Infliximab	-	15 mg Prednisolone
f	33	Rheumatoid Arthritis	Certolizumab pegol	-	-
f	47	Psoriasis	Ixekizumab	-	-
m	83	Rheumatoid Arthritis	Etanercept	-	2.5 mg Prednisolone
m	38	Crohn's disease	Vedolizumab	-	-
f	53	Rheumatoid Arthritis	-	Leflunomide	7 mg Prednisolone
f	24	Systemic lupus erythematosus	-	Hydroxychloroquine	-
m	42	Psoriasis	Adalimumab	-	-
f	54	Rheumatoid Arthritis	Adalimumab	-	-
m	58	Spondyloarthropathy	Secukinumab	-	-
f	51	Psoriasis	Secukinumab	-	-
f	53	Crohn's disease	Infliximab	-	-
m	61	Psoriasis	Ustekinumab	-	-
m	36	Systemic lupus erythematosus	Belimumab	Hydroxychloroquine	-
f	89	Myositis	-	-	2.5 mg Prednisolone